Progressing to study Radspherin® in the first-line treatment setting for ovarian cancer IND clearance is now obtained for both lead indications for Radspherin®
This marks the first IND clearance for initiation of Radspherin® clinical trials in the US
At 18 months, no patients at the recommended dose of 7 MBq experienced peritoneal recurrences Robust safety profile demonstrated, no serious adverse events related to Radspherin® reported Presentation on October 4, 2023, at 11:55 a.m. CET (5:55 a.m. EDT)
Recommended dose of 7 MBq established following completion of dose escalation; no dose-limiting toxicity observed Presentation on September 30, 2023
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023, at 9:30 a.m. ET.
Median PFS (progression free survival) was not reached at 15 months, and no patients at recommended dose of 7 MBq had peritoneal recurrences All dose levels of Radspherin®, including recommended dose of 7 MBq, were well tolerated at 15 months with no serious adverse events related to Radspherin® reported Radspherin® is currently being evaluated in two ongoing Phase 1/2A trials for the treatment of peritoneal carcinomatosis from colorectal cancer and ovarian cancer Poster discussion session on June 5, 2023 at 1:15 p.m. ET
Publications highlight the safety and tolerability of Radspherin® for patients and those externally exposed to radiation, all dose levels were well tolerated with dose level toxicity (DLT) not reached.
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced strong progress with clinical trials, including patient recruitment and efficacy signals. Further updates will be provided in an upcoming investor conference call.